FDA Clearance Tracker · P970042-S004
MEDSTONE STS LITHOTRIPTER FOR THE TREATMENT OF SYMPTOMATIC, SOLITARY, RADIOLUCENT, NON-CALCIFIED GALLSTONES
Last checked: Nov 20, 2026Latest source record: Jan 28, 2003 (this decision)Source: openFDAMethods & limitations
Decided
Jan 28, 2003
Approved
Time to decision
179 days
Received Aug 2, 2002. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P970042-S004
- Device name
- MEDSTONE STS LITHOTRIPTER FOR THE TREATMENT OF SYMPTOMATIC, SOLITARY, RADIOLUCENT, NON-CALCIFIED GALLSTONES
- Applicant
- Medstone Intl., Inc.
- Applicant location
- Aliso Viejo, CA
- Received
- Aug 2, 2002
- Decided
- Jan 28, 2003
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P970042
Device type
- Device class
- Class III
- Specialty
- GI, Urology & NephrologyUrology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR 1) A CHANGE IN THE INCLUSION AGE LIMIT FOR THE POST-APPROVAL STUDY FROM 18-70 TO 18 AND OVER; 2) A CHANGE IN THE POST APPROVAL STUDY'S MONITORING FROM RSI TO MEDSTONE; AND 3) A CHANGE IN THE POST-APPROVAL STUDY'S MEDICAL MONITOR FROM RSI TO MICHAEL ALBERT, M.D.
Source documents
Other decisions for Medstone Intl., Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.